Quell Therapeutics
PrivateLast Round
Strategic
Jun 9, 2023
Est. Valuation
$34.09M
Total Funding Raised
$405.4M
Company Overview
Quell Therapeutics is a biotechnology company that develops engineered T-regulatory (Treg) cell therapies to treat severe immune-mediated and inflammatory diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Quell Therapeutics Comparables
Compare Quell Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Sonoma Biotherapeutics | 88% | |
| GentiBio | 84% | |
| ActiTrexx GmbH | 83% |
Quell Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Strategic | Jun 9, 2023 | ||||
| Series B | Nov 29, 2021 | ||||
| Series A Extension | Feb 11, 2021 | ||||
| Series A | May 20, 2019 | ||||
| Series A | Mar 29, 2019 |
Quell Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Janus Henderson Group | Series B |
| SV Health Investors | Series B |
| Syncona | Series B, Series A, Series A Extension |
| Ridgeback Capital | Series B |
| Future Fund | Series B |
| Fidelity Management & Research Company | Series B |
| British Patient Capital | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 25, 2025
Presenting data at ACR Convergence 2025.
- Oct 25, 2025
Will present data for QEL-005 CAR-Treg cell therapy at ACR Convergence 2025.
Quell Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Quell Therapeutics's valuation, stock price, and market status.
Is Quell Therapeutics a public or private company?
Quell Therapeutics is a private company.
What is the current stock price of Quell Therapeutics?
Quell Therapeutics is a private company, so its shares have no public market price. Caplight tracks Quell Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Quell Therapeutics worth (valuation)?
Quell Therapeutics's valuation is estimated at $34.1M based on funding round data.
Can I buy Quell Therapeutics stock?
Quell Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Quell Therapeutics's last funding round?
Quell Therapeutics's most recent funding round was Strategic on June 9, 2023.
Who are the main investors in Quell Therapeutics?
Key investors in Quell Therapeutics include SV Health Investors, Syncona, Ridgeback Capital, Fidelity Management & Research Company, Albion Capital.
Will Quell Therapeutics IPO soon?
No public IPO plans have been announced for Quell Therapeutics.
How can I track Quell Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Quell Therapeutics's shares on secondary markets.